<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496012</url>
  </required_header>
  <id_info>
    <org_study_id>NSR-REP-01</org_study_id>
    <secondary_id>2015-003958-41</secondary_id>
    <nct_id>NCT03496012</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AAV2-REP1 for the Treatment of Choroideremia</brief_title>
  <acronym>STAR</acronym>
  <official_title>A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nightstar Therapeutics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nightstar Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy and safety of a single sub-retinal
      injection of AAV2-REP1 in subjects with Choroideremia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3 clinical trial of a gene therapy vector made from adeno-associated virus
      (AAV) called AAV2-REP1 for the treatment of Choroideremia. Participating subjects will be
      required to attend a screening visit during which their suitability for the study will be
      assessed, and eligible subjects will be randomized to either AAV2-REP1 treatment or the
      control group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group Study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes-assessors will be masked to whether the subjects is in the treated or the control group.
Subjects and trial centres will be masked to whether high or low dose has been administered in the treated group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>12 Months</time_frame>
    <description>ETDRS visual acuity chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fundus autofluorescence (AF)</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in AF (mm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography</measure>
    <time_frame>12 Months</time_frame>
    <description>Ellipsoid Zone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microperimetry</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in Sensitivity (dB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>12 Months</time_frame>
    <description>Pelli-Robson Chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color Vision</measure>
    <time_frame>12 Months</time_frame>
    <description>Farnsworth-Munsell 100 Hue Test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Choroideremia</condition>
  <arm_group>
    <arm_group_label>AAV2-REP1 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single administration of high-dose AAV2-REP1 in one eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AAV2-REP1 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single administration of low-dose AAV2-REP1 in one eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated control subjects will be observed for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AAV2-REP1</intervention_name>
    <description>Sub-retinal injection of AAV2-REP1 after vitrectomy.</description>
    <arm_group_label>AAV2-REP1 High Dose</arm_group_label>
    <arm_group_label>AAV2-REP1 Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are willing and able to give informed consent for participation in the study.

          -  Are male and ≥18 years of age.

          -  Have a genetically-confirmed diagnosis of CHM.

          -  Have active disease clinically visible within the macular region in the study eye.

          -  Fulfill pre-defined visual acuity criteria.

        Exclusion Criteria:

          -  Have a history of amblyopia in the eligible eye.

          -  Are unwilling to use barrier contraception methods, for a period of 3 months, if
             treated with AAV2-REP1.

          -  Previous intraocular surgery performed in the study eye within 3 months of Visit 1.

          -  Have any other significant ocular or non-ocular disease/disorder which, in the opinion
             of the investigator, may either put the subjects at risk because of participation in
             the study, or may influence the results of the study, or the subject's ability to
             participate in the study.

          -  Have participated in another research study involving an investigational product in
             the past 12 weeks or received a gene/cell-based therapy at any time previously.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nightstar Therapeutics</last_name>
    <phone>+44 (0)20 7611 2077</phone>
    <email>researchenquiries@nightstartx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jules Stein Eye Institute, University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center, Edward S Harkness Eye Inst</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest,</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University Health Centre</name>
      <address>
        <city>Québec</city>
        <zip>H3A 0E7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, Eye Care Centre</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 3N9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Eye Clinic Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manchester Centre for Genomic Medicine, St Mary's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oxford Eye Hospital, John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NightstaRx</keyword>
  <keyword>NSR-REP1</keyword>
  <keyword>Choroideremia</keyword>
  <keyword>CHM</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>AAV</keyword>
  <keyword>REP1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroideremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

